NCT03546452 is a clinical trial of in vitro NGS-panel in Malignant Hydrothorax, sponsored by Shanghai Chest Hospital.

Who is sponsoring NCT03546452?

NCT03546452 is sponsored by Shanghai Chest Hospital.

What drugs are being tested in NCT03546452?

Interventions in NCT03546452: in vitro NGS-panel.

What condition does NCT03546452 study?

NCT03546452 studies Malignant Hydrothorax, NSCLC.

Is NCT03546452 still recruiting?

NCT03546452 is currently status unknown. Last updated 7 June 2018.

Last reviewed 2018-06-07 · How we verify

NCT03546452

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Prospective Study to Evaluate the Consistency of Next-Generation Sequencing(NGS)-Panels by Using Malignant Hydrothorax Form NSCLC

Status unknown Last updated 7 June 2018

What this trial tests

trial testing in vitro NGS-panel in Malignant Hydrothorax in 50 participants. Status unknown.

Timeline

18 May 2018

Primary endpoint
30 September 2018

1 May 2019

Quick facts

Lead sponsor	Shanghai Chest Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	50
Start date	18 May 2018
Primary completion	30 September 2018
Estimated completion	1 May 2019
Sites	1 location across China

Drugs / interventions tested

in vitro NGS-panel

Conditions studied

Malignant Hydrothorax — all drugs for Malignant Hydrothorax →
NSCLC — all drugs for NSCLC →

Sponsor

Shanghai Chest Hospital

Who can join

Adults 18 to 70, any sex, with Malignant Hydrothorax or NSCLC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective study to evaluate consistency of different NGS-panel. Cell free DNA is purified from each malignant hydrothorax from NSCLC .Different NGS-panels are applied to perform in vitro diagnosis to detect Single Nucleotide Variants(SNV) and to calculate TMB value in these DNA samples.Consistency of enrolled NGS-panels are then evaluated by statistical analysis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Standardization of pleural effusion-based tumor mutation burden (TMB) estimation using capture-based targeted sequencing.
Yu Y, Shen L, Ji W, Lu S. · · 2021 · cited 4× · PMID 33569442 · DOI 10.21037/atm-20-7702

Verify or expand the search:

Other Shanghai Chest Hospital trials

Trials by the same sponsor.

NCT07515027 — Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung · NA · recruiting
NCT07479628 — Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma · Phase 2 · not yet recruiting
NCT07528066 — Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC · recruiting
NCT07331727 — Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation · NA · not yet recruiting
NCT07320768 — Renal Denervation Combined With Pulsed Field Ablation to Prevent Blanking-Period Recurrence in Persistent Atrial Fibrill · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03546452 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Chest Hospital
Last refreshed: 7 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03546452.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing